| Description | Rovelizumab, a humanized monoclonal leukointegrin antibody, targets CD11/CD18 cell adhesion proteins. It has potential applications in the research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI), and stroke [1]. |
| molecular weight | N/A |
| CAS | 339086-79-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 years |